Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta‐analysis. (8th February 2022)

• Record Type: Journal Article
• Authors: Verdijk, Joey P.A.J.; van Kessel, Mike A.; Oud, Matthijs; Kellner, Charles H.; Hofmeijer, Jeannette; Verwijk, Esmée; van Waarde, Jeroen A.
• Is Part Of: Acta psychiatrica Scandinavica. Volume 145:Number 4(2022)
• Page Start: 343
• Page End: 356
• Publication Date: 2022-02-08
• Subjects: cognitive outcome -- electroconvulsive therapy -- meta‐analysis -- pharmacological interventions -- systematic review; Psychiatry -- Periodicals; 616.89
• DOI: 10.1111/acps.13397
• Languages: English
• ISSNs: 0001-690X

Abstract

Abstract: Objective: The authors conducted a systematic review and meta‐analysis of pharmacological interventions to diminish cognitive side effects of ECT. Methods: Electronic databases of Pubmed, PsycInfo, Embase and Scopus were searched from inception through 1 April, 2021, using terms for ECT (e.g. electroconvulsive therapy ), cognitive outcome (e.g. cogni* ) and pharmacological intervention (e.g. calcium channel blocker and general terms, like protein ). Original studies with humans receiving ECT were included, which applied pharmacological interventions in comparison with placebo or no additive intervention to diminish cognitive side effects. Data quality was assessed using Risk of Bias and GRADE. Random‐effects models were used. PROSPERO registration number was CRD42021212773. Results: Qualitative synthesis (systematic review) showed 52 studies reporting sixteen pharmacological intervention‐types. Quantitative synthesis (meta‐analysis) included 26 studies (1387 patients) describing twelve pharmacological intervention‐types. Low‐quality evidence of efficacy was established for memantine (large effect size) and liothyronine (medium effect size). Very low‐quality evidence shows effect of acetylcholine inhibitors, piracetam and melatonin in some cognitive domains. Evidence of no efficacy was revealed for ketamine (very low‐quality), herbal preparations with anti‐inflammatory properties (very low to low‐quality) and opioid receptor agonists (low‐quality). Conclusion: Memantine and liothyronine are promising for further research and future application. Quality of evidence was low because of differences in ECT techniques, study populations and cognitive measurements. These findings provide a guide for rational choices of potential pharmacological intervention research targets to decrease the burden of cognitive side effects of ECT. Future research should be more uniform in design and attempt to clarify pathophysiological mechanisms of cognitive side effects of ECT.